The Role of High-flow Nasal Cannula Therapy in the Treatment of Acute Carbon Monoxide Poisoning
NCT ID: NCT03818841
Last Updated: 2019-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
96 participants
INTERVENTIONAL
2019-02-01
2022-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utility of High Flow Nasal Cannula in CO Toxicity
NCT03342209
High Flow Nasal Cannulae vs Venturi Mask in Respiratory Failure Due to Pneumonia
NCT03515031
Early Initiation of High-flow Nasal Cannula Oxygen Therapy in Patients With Acute Respiratory Failure in the Emergency Department: A Before-after Study
NCT03447457
Helmet Noninvasive Ventilation vs. High-flow Nasal Cannula in Moderate-to-severe Acute Hypoxemic Respiratory Failure
NCT04502576
Conduct of Nasal High Flow Oxygen in Acute Respiratory Failure
NCT03311087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-flow nasal cannula group
Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
High-flow nasal cannula device
Patients will be randomly allocated to this treatment
Non-rebreathing oxygen mask group
In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
Non-rebreathing oxygen mask group
Patients will be randomly allocated to this treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High-flow nasal cannula device
Patients will be randomly allocated to this treatment
Non-rebreathing oxygen mask group
Patients will be randomly allocated to this treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Carbon monoxide intoxication as major problem leading to emergency department admission
* Carboxyhemoglobin (COHb) concentration 10% at the time of enrolment
Exclusion Criteria
* Glasgow coma scale ≤ 13
* Refusal to give consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Università degli Studi del Piemonte Orientale Amedeo Avogadro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luigi M Castello, MD
Role: PRINCIPAL_INVESTIGATOR
A.O.U. Maggiore della Carità di Novara
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AOU Maggiore della Carità di Novara. Emergency Medicine Department. Department of Translational Medicine.
Novara, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Brotfain E, Zlotnik A, Schwartz A, Frenkel A, Koyfman L, Gruenbaum SE, Klein M. Comparison of the effectiveness of high flow nasal oxygen cannula vs. standard non-rebreather oxygen face mask in post-extubation intensive care unit patients. Isr Med Assoc J. 2014 Nov;16(11):718-22.
Jeon SB, Sohn CH, Seo DW, Oh BJ, Lim KS, Kang DW, Kim WY. Acute Brain Lesions on Magnetic Resonance Imaging and Delayed Neurological Sequelae in Carbon Monoxide Poisoning. JAMA Neurol. 2018 Apr 1;75(4):436-443. doi: 10.1001/jamaneurol.2017.4618.
Rose JJ, Wang L, Xu Q, McTiernan CF, Shiva S, Tejero J, Gladwin MT. Carbon Monoxide Poisoning: Pathogenesis, Management, and Future Directions of Therapy. Am J Respir Crit Care Med. 2017 Mar 1;195(5):596-606. doi: 10.1164/rccm.201606-1275CI.
Nishimura M. High-flow nasal cannula oxygen therapy in adults. J Intensive Care. 2015 Mar 31;3(1):15. doi: 10.1186/s40560-015-0084-5. eCollection 2015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO-HFNC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.